Astellas Announces Cancellation of Treasury Shares

Tokyo, Japan, May 11, 2016 – Astellas Pharma Inc. (TSE: 4503; President and CEO: Yoshihiko Hatanaka, hereinafter called “the Company”) announced that at the meeting of the Board of Directors held today, a resolution was adopted that the Company will cancel its treasury shares, pursuant to Article 178 of the Companies Act.

Particulars
1. Class of shares to be cancelled     Common stock of the Company
2. Number of shares to be cancelled   68 million shares
   (Representing 3.06% of issued shares prior to cancellation)
3. Cancellation date                   June 20, 2016

The cancellation stated above will be subject to the approval for the reversal of general reserve and reserve for retirement benefits, which will be included in the proposal of the appropriation of retained earnings, at the Company’s Ordinary General Meeting of Shareholders to be held on June 20, 2016.

(Reference)
1. Following cancellation, the Company will have 2,153,823,175 issued shares.
2. Total number of the Company’s treasury shares after cancellation will be 28,844,512.

(Expected numbers of shares described above 1 and 2 were calculated on the basis of the issued shares and the Company’s treasury shares as of March 31, 2016, respectively.)